<div class="section">
<a class="named-anchor" id="S1">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d9279350e269">Background</h5>
<p id="P5">Heart failure (HF) in developing countries is poorly described. We compare
characteristics
and prognosis of HF in Tanzania vs. Sweden.
</p>
</div><div class="section">
<a class="named-anchor" id="S2">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d9279350e274">Methods</h5>
<p id="P6">A prospective cohort study was conducted from the Tanzania HF study (TaHeF)
and the
Swedish HF Registry (SwedeHF). Patients were compared overall (n 427 vs. 51,060) and
after matching 1:3 by gender and age ± 5 years (n 411 vs. 1232). The association between
cohort and all-cause mortality was assessed with multivariable Cox regression.
</p>
</div><div class="section">
<a class="named-anchor" id="S3">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d9279350e279">Results</h5>
<p id="P7">In the unmatched cohorts, TaHeF (as compared to SwedeHF) patients were
younger (median
age [inter-quartile range] 55 [40–68] vs. 77 [64–84] years, p < 0.001) and more
commonly
women (51% vs. 40%, p < 0.001). The three-year survival was 61% in both cohorts.
In
the matched cohorts, TaHeF patients had more hypertension (47% vs. 37%, p < 0.001),
more anemia (57% vs. 9%), more preserved EF, more advanced HF, longer duration of
HF, and less use of beta-blockers. Crude mortality was worse in TaHeF (HR 2.25 [95%
CI 1.78–2.85], p < 0.001), with three-year survival 61% vs. 83%. However, covariate-adjusted
risk was similar (HR 1.07, 95% CI 0.69–1.66; p = 0.760). In both cohorts, preserved
EF was associated with higher mortality in crude but not adjusted analysis.
</p>
</div><div class="section">
<a class="named-anchor" id="S4">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d9279350e284">Conclusions</h5>
<p id="P8">Compared to in Sweden, HF patients in Tanzania were younger and more commonly
female,
and after age and gender matching, had more frequent hypertension and anemia, more
severe HF despite higher EF, and worse crude but similar adjusted prognosis.
</p>
</div>